Latest Breaking News On - Clinical oncology genitourinary cancers symposium - Page 5 : comparemela.com

Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium

19.12.2023 - SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral . Seite 1

United statesSan franciscoHimisha beltranDrug administrationMd dana farber cancer instituteHarpoon therapeutics incHarpoon therapeutics abstractRapid oral presentationClinical oncology genitourinary cancers symposiumAmerican societyActivating constructT cell engagerNeuroendocrine prostate cancerNeuroendocrine neoplasmsRapid oral abstract sessionProstate cancer

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the.

United statesBritish columbiaDavid parkinsonDavid woodPharma incProstate cancer foundationQuarter fiscalClinical oncology genitourinary cancers symposiumOutstanding shareOpen market salePrivate securities litigation reform actChief financialEssa pharma inc

Next-Generation Aniten Masofaniten Gains Momentum in mCRPC

The emergence of a novel class of compounds, known as anitens, potentially offers clinicians the ability to elongate responses for patients with metastatic castration-resistant prostate cancer, with the first-in-class N-terminal domain androgen receptor inhibitor masofaniten showing promise as it moves to the phase 2 portion of a phase 1/2 trial.

New jerseyUnited statesMemorial sloan kettering cancer centerNew yorkAndrew laccettiEuropean society for medical oncology congressClinical oncology genitourinary cancers symposiumEuropean societyMedical oncology congressResearch efforts are underway in the prostate cancer paradigm

Prostate Cancer Is Not Just an Old Man s Disease

Spreading this message can save lives

New yorkUnited statesMemorial sloan kettering cancer centerNew york universityStacy loebAaron katzLorenzo cohenGabe canaleYork university langoneGrade groupUniversity of california san franciscoSurveillance patients internationalUniversity of texas md anderson cancer centerBlue cure men health college tourMd anderson integrative medicine programYork university

Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer

Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPeter dannenbaumSusan galbraithDamini chokshiEliav barrChrissy trankJulie cunninghamEuropean unionMerck research laboratoriesMerck co incDrug administrationOncologic drugs advisory committeeExchange commissionProstate cancer working groupStatement of merck co incNew drug application